Our latest research report titled "Infertility Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Test Kits, Sample, and End User, Geography" indicates that the market is projected to expand from US$ 424.20 million in 2022 to US$ 820.08 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.6% from 2022 to 2030.

The anticipated growth in the market is primarily driven by the rising incidence of infertility among both genders and the continuous advancements in infertility testing technologies. Additionally, the increasing number of awareness campaigns is expected to create further opportunities for the infertility testing market. Conversely, the growth of this market is somewhat hindered by a lack of awareness and certain limitations associated with infertility testing kits.

A study titled "Fertility and Infertility: Definition and Epidemiology," published by Elsevier B.V., reveals that infertility affects approximately 8-12% of couples globally. This percentage is on the rise due to various factors, including modern lifestyle choices, health issues, and the trend of delaying parenthood. In men, infertility is frequently linked to difficulties in semen ejaculation, low sperm count, or abnormalities in sperm shape (morphology) and movement (motility). For women, infertility can stem from issues related to the uterus, ovaries, fallopian tubes, or endocrine system.

In 2022, North America held a significant share of the global infertility testing market. This region's market is divided into the US, Canada, and Mexico. The growth in North America is fueled by a high prevalence of infertility, increased awareness of testing options among both men and women, a growing female population suffering from polycystic ovary syndrome (PCOS), the trend of later pregnancies, and the easy access to infertility test kits via e-commerce platforms. Furthermore, lifestyle changes, including unhealthy dietary habits, have contributed to infertility and related gynecological disorders, further driving the market. Technological innovations in ovulation monitoring devices are also enhancing market growth. Additionally, the rising rates of smoking and tobacco use are expected to contribute to increased infertility cases, thereby boosting market expansion. The demand for self-testing and remote monitoring solutions among women, along with the introduction of innovative products, is likely to create lucrative opportunities in the market.

The rise in awareness campaigns is significantly contributing to the growth opportunities within the infertility testing market. Traditionally, infertility issues have been attributed to women, but recent advancements in science and research have shifted this perception, highlighting the importance of male infertility as well. More men are now being tested and educated about the factors that contribute to infertility. While some regions are making progress in this regard, many areas still lack awareness about available testing and treatment options.

This situation presents a chance for organizations to conduct awareness campaigns that address this critical issue affecting a substantial number of men worldwide. For example, in November 2020, Nova IVF Fertility, in partnership with the Times of India, launched the "Fertile Conversations" initiative, which facilitated discussions on infertility issues among both genders with experts. Similarly, Cooper Genomics, a subsidiary of Cooper Surgical, initiated the National Infertility Awareness Week: Infertility Uncovered campaign to educate the public about infertility and inform patients about the products and services available to support families globally. Such awareness initiatives are expected to provide valuable platforms for companies, thereby enhancing revenue opportunities in this evolving market.

**Insights Based on Type**
The infertility testing market analysis is categorized by type into male and female segments. In 2022, the female infertility testing segment commanded a larger market share. However, the male infertility testing segment is projected to experience a higher CAGR of 9.2% during the forecast period.

Factors contributing to the significant market share of female infertility testing include declining fertility rates among women, a rise in gynecological health issues, the increasing stress levels associated with busy lifestyles, and lower egg counts. The availability of a wide range of female infertility tests also supports the growth of this segment.

**Insights Based on Test Kits**
The infertility testing market is further segmented by test kits, including human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. In terms of revenue, the human follicular stimulating hormone (FSH) test kits segment led the market in 2022 and is expected to achieve the highest CAGR of 9.2% during the forecast period.

FSH test kits are utilized to measure the concentration of the FSH hormone in the bloodstream, often for assessing fertility issues, menopause, or sexual development problems. The growth of advanced biosimilar FSH products, regulatory approvals, improved market access, and technological advancements in FSH kit production are anticipated to drive global market growth.

**Insights Based on End User**
The infertility testing market is categorized by end user into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is projected to register the highest CAGR of 9.0% during the forecast period.

Key players in the market are adopting strategies such as expansion, partnerships, launching new products, and acquiring new customers to capitalize on existing business opportunities.

- In August 2023, Trajan Scientific and Medical provided CE-IVD registered Mitra devices to Fertilly, which launched Europe?s first at-home fertility testing kits using dried blood micro samples with VAMS technology.
- In February 2021, Fertility Focus collaborated with ExSeed Health to offer at-home sperm testing solutions for those planning to conceive.
- In June 2020, Modern Fertility introduced ovulation and pregnancy test kits along with a mobile application to centralize fertility-related data.
- In March 2020, Proov received FDA approval for its home ovulation test kit.

The primary and secondary sources utilized in preparing the infertility testing market report include the US Food and Drug Administration, the Centers for Disease Control and Prevention (CDC), and the Global Burden of Disease Study.